AMENDMENT #2 TO CO-PROMOTION AGREEMENTCo-Promotion Agreement • July 28th, 2020 • Exagen Inc. • Services-medical laboratories
This Amendment #2 ("Amendment") is signed as of the signature date(s) below and made effective as of 18 June, 2020 ("Effective Date") by and between Janssen Biotech, Inc. ("JBI") and Exagen Diagnostics Inc. ("Exagen") and amends that Co-Promotion Agreement effective as of December 10, 2018 by and between JBI and Exagen, as previously amended (“Agreement”). All terms not otherwise defined herein shall have the meaning ascribed to such terms in the Agreement.
AMENDMENT #1 TO CO-PROMOTION AGREEMENTCo-Promotion Agreement • July 28th, 2020 • Exagen Inc. • Services-medical laboratories
This Amendment #1 ("Amendment") is signed as of the signature date(s) below and made effective as of January 1, 2019 ("Effective Date") by and between Janssen Biotech, Inc. ("JBI") and Exagen Diagnostics Inc. ("Exagen") and amends that Co-Promotion Agreement effective as of December 10, 2018 by and between JBI and Exagen, with contract reference number C2018017807 and iCD reference number 1251568 ("Agreement"). All terms not otherwise defined herein shall have the meanings ascribed to such terms in the Agreement.
